Exabis Library
Welcome to the e-CCO Library!
P777: Comparison of costs of different biologic therapies after dose optimisation
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P777: Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P777: The cancer incidence in paediatric onset inflammatory bowel disease: a population-based study from Denmark 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P777: Ursodeoxycholic acid and its taurine/glycine conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P778 Longitudinal trajectory of fatigue in inflammatory bowel disease patients: a prospective study 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P778: Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin  (REASUC study)
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P778: Microbial characterization of paediatric inflammatory bowel disease and stratification into disease severity groups
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P778: Real-world drug treatment costs for ulcerative colitis and Crohn’s disease patients treated with vedolizumab vs. anti-TNFα: Results from a German retrospective chart review study
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P778: Risk of cancer in paediatric onset inflammatory bowel disease: a nationwide cohort study 1977–2014 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P779 Intestinal cancer associated with Crohn’s disease: difference between those with short duration and those with long duration 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P779: CD patients in deep remission harbor a high dysbiosis index similar to active CD at diagnosis, yet both are higher in comparison to healthy controls
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P779: Clinical outcome with biological therapy in ulcerative colitis: Real-world clinical setting from a multi-centre observational study
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P779: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P779: Extra intestinal manifestations and other comorbidities in Crohn’s disease and Ulcerative colitis are equally likely to appear before IBD diagnosis: a Danish nationwide registry study from 2003 to 2015 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P780 Proteinuria is associated with the development of Crohn’s disease: a nationwide population-based study 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P780: 3-oxo-C12:2-HSL, a new N-acyl-homoserine lactone identified in gut ecosystem exerts an anti-inflammatory effect and does not modify paracellular permeability
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P780: Interchangeability by a biosimilar of infliximab: What do patients think?
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P780: Medical treatment and surgery in patients with elderly-onset inflammatory bowel disease: 3-year follow-up of Epi-IBD 2010–2011 cohorts 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P780: Prognosis and optimal treatment for 5-aminosalicylic acid-intolerant patients with Ulcerative Colitis
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P781 Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM